Company signals · Biotech & Pharma
Ratio Therapeutics
1 signal in the current window, with MitchelLake's leadership read on each.
Market context: MitchelLake's Talent Market Index sits at 98.6 (Neutral), down 1.4 on the prior month; Americas hiring signal is running easing (-2.6pts).
Ratio Therapeutics: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 19 tracked companies; 0.1% of MitchelLake's Americas signal flow.
Signals at Ratio Therapeutics
More signals across Biotech & Pharma
Partnership · Americas
Bristol Myers Squibb →Bristol Myers Squibb entered into a major alliance with Chinese pharmaceutical firm Hengrui involving up to 13 drugs and valued at up to $15.2 billion. This represents significant international collaboration in drug development and commercialization.
Partnership · Americas
BioDuro →BioDuro forms strategic partnership with CTI Biotechnology to create integrated platform from discovery to IND submission for preclinical drug development
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Intelligence powered by Autonodal ↗